CTIS2024-510991-19-00进行中（未招募）1 期
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy - OV-AML-1231
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 177
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Men and women =18 years old., Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study., Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts)., Previously untreated AML except may have received emergency leukapheresis, hydroxyurea, and/or 1 dose of 1 to 2 g/m2 cytarabine before study entry to control hyperleukocytosis., Deemed unfit for intensive chemotherapy by meeting the criterial listed in the Protocol, Adequate liver and renal function, as per defined in the Protocol, Women of childbearing potential (WOCBP), defined as fertile women between menarche and post menopause unless permanently sterile, must have a negative highly sensitive serum ß-human chorionic gonadotropin (ß-hCG) or urine pregnancy test at screening, Must be willing to use contraception as consistent with institutional guidelines regarding the use of contraceptive methods for participants participating in clinical studies, Participants with HIV infection are eligible for the trial if the criteria included in the Protocol are met
排除标准
- •Any prior treatment for AML or myelodysplastic syndrome (MDS) (except those outlined in Inclusion Criterion #4), History of prior HSCT, Active hepatitis B or C infection or other clinically active liver diseases as defined in the Protocol, Congestive heart failure severity that is New York Heart Association Class III or IV, Unstable angina, Known allergies, hypersensitivity, or intolerance to cusatuzumab, venetoclax, or azacitidine or their excipients (e.g., mannitol, an excipient of azacitidine), Inability or difficulty swallowing capsules/tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function, Any condition for which, in the investigator’s opinion, participation would not be in the best interest of the participant (e.g., compromise the well-being) or physical limitations that could prevent, limit, or confound the protocol-specified assessments, Major surgery (e.g., requiring general anesthesia) =4 weeks prior to initiation of study treatment, Participant has received a HMA for MDS or myeloproliferative neoplasm, Leukemic involvement in the central nervous system, Participants with acute promyelocytic leukemia (APL), ECOG performance status of 4 for participants 18 to 74 years of age and ECOG performance status of 3 or 4 for participants =75 years of age, Use of immune suppressive agents =4 weeks before the first administration of cusatuzumab. Participants may be included if free of systemic corticosteroids >5 days before the first administration of cusatuzumab with the exception of corticosteroids at physiologic replacement doses, Received a live, attenuated vaccine within 4 weeks prior to initiation of study drug, Active malignancies (i.e., progressing or requiring treatment change in the last 24 months), including advanced malignant hepatic tumors, other than the disease being treated under study. Exceptions listed in the protocol., Any active systemic infection
研究者
相似试验
招募中
2 期
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated MyelofibrosisMyelofibrosis2024-513605-31-00Karyopharm Therapeutics Inc.28
进行中（未招募）
1 期
A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated MyelofibrosisMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003809-60-HUKaryopharm Therapeutics Inc.112
进行中（未招募）
1 期
A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated MyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-003809-60-PLKaryopharm Therapeutics Inc.112
进行中（未招募）
1 期
A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated MyelofibrosisMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003809-60-GRKaryopharm Therapeutics Inc.112
进行中（未招募）
1 期
Studio per valutare la sicurezza e l'efficacia del selinexor vs. trattamento di scelta del medico in pazienti con mielofibrosi già precedentemente trattata.MyelofibrosisEUCTR2020-003809-60-ITKARYOPHARM THERAPEUTICS, INC.112